ATE82506T1 - Stabilisierung von wachstumshormonen. - Google Patents

Stabilisierung von wachstumshormonen.

Info

Publication number
ATE82506T1
ATE82506T1 AT87307406T AT87307406T ATE82506T1 AT E82506 T1 ATE82506 T1 AT E82506T1 AT 87307406 T AT87307406 T AT 87307406T AT 87307406 T AT87307406 T AT 87307406T AT E82506 T1 ATE82506 T1 AT E82506T1
Authority
AT
Austria
Prior art keywords
stabilization
growth hormone
amino acids
growth
stabilizers
Prior art date
Application number
AT87307406T
Other languages
English (en)
Inventor
Edwin J Hamilton Jr
Bruce D Burleigh
Original Assignee
Imcera Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8198005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE82506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imcera Group Inc filed Critical Imcera Group Inc
Application granted granted Critical
Publication of ATE82506T1 publication Critical patent/ATE82506T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
AT87307406T 1987-08-21 1987-08-21 Stabilisierung von wachstumshormonen. ATE82506T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87307406A EP0303746B2 (de) 1987-08-21 1987-08-21 Stabilisierung von Wachstumshormonen

Publications (1)

Publication Number Publication Date
ATE82506T1 true ATE82506T1 (de) 1992-12-15

Family

ID=8198005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87307406T ATE82506T1 (de) 1987-08-21 1987-08-21 Stabilisierung von wachstumshormonen.

Country Status (5)

Country Link
EP (1) EP0303746B2 (de)
AT (1) ATE82506T1 (de)
DE (1) DE3782737T3 (de)
ES (1) ES2044941T5 (de)
HU (1) HU202117B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
AU4278393A (en) * 1992-04-07 1993-11-08 Mallinckrodt Veterinary, Inc. Lyophilized somatotropin formulations
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
DE69420872T2 (de) * 1994-06-17 2000-01-13 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
NZ535205A (en) 1999-10-04 2006-01-27 Chiron Corp Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions
KR20080011353A (ko) * 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
AU8111301A (en) 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
EP1599222B1 (de) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US8409586B2 (en) 2006-07-06 2013-04-02 Daewoong Co., Ltd. Stable liquid formulation of human growth hormone
AR076640A1 (es) 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
AU2011234268B2 (en) * 2010-03-31 2015-07-02 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
US20130089912A1 (en) * 2011-10-06 2013-04-11 Gloria Elliott Methods and compositions for the stabilization of biologic material
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー，リミテッド ヒト成長ホルモンを含有する安定した液状製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (de) * 1985-03-06 1987-09-23 American Cyanamid Company Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions

Also Published As

Publication number Publication date
DE3782737T3 (de) 1999-05-20
EP0303746A1 (de) 1989-02-22
ES2044941T4 (es) 1996-07-16
HUT44706A (en) 1988-04-28
HU202117B (en) 1991-02-28
EP0303746B2 (de) 1998-12-02
EP0303746B1 (de) 1992-11-19
ES2044941T3 (es) 1994-01-16
ES2044941T5 (es) 1999-02-16
DE3782737T2 (de) 1993-04-01
DE3782737D1 (de) 1992-12-24

Similar Documents

Publication Publication Date Title
ATE82506T1 (de) Stabilisierung von wachstumshormonen.
PT82978B (pt) Processo para a producao de hormonas de crescimento recombinantes bio-activas secas
DE3583518D1 (de) Produktion von eiern.
DE69233188D1 (de) Hormonanaloge mit mehreren ctp-erweiterungen
EG19012A (en) Low volatility salts
SE8505048D0 (sv) Nutritionsemulsion med syretransporterande egenskaper
DE3881364T2 (de) Verfahren zur Herstellung und Zusammensetzungen von Kollagen-Derivaten.
HK1006154A1 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
ES2052609T3 (es) Utilizacion de derivados de piridoxina en la profilaxis y terapia de hiperlipidemias y aterosclerosis.
PT87658A (pt) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet loesung enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3867445D1 (de) Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren.
ATE114470T1 (de) Behandlung von intraocularem druck mit einer synergistischen kombination zur ophthalmischen verwendung.
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
GR3006748T3 (de)
DE69016087T2 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
FI98891B (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
ES557426A0 (es) Un procedimiento para la preparacion de una sal de dobutamina y acido lactobionico.
EP0142597A3 (en) Curative composition for buerger's disease
DK15088D0 (da) Antibakterielt lyofiliseret praeparat
DE3167839D1 (en) Method for preparing n-(4-(((2,4-diamino-6-pteridinyl)-methyl)methylamino)benzoyl)glutamic acid
ES8706838A1 (es) Metodo para conservar cueros, pellejos y pieles crudos de animales
EP0260092A3 (en) Optically active beta-amino acid derivatives and their salts, and processes for producing the same
ES2068377T3 (es) Composicion pesticida.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee